In the past month, FibroBiologics, Inc. (NASDAQ: FBLG) has disclosed the advancement of its fibroblast therapy platform into additional indications, including: On March 2, 2026, the company announced ...

On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...

HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...

HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...

Southampton scientists working to improve survival for cancer patients have identified a key characteristic of the disease that could make treatment more effective. Many patients do not respond well ...

A new study reviews how cancer-associated fibroblasts (CAFs) influence lymph node metastasis. Researchers identified various CAF subsets that interact with the tumor microenvironment, promoting cancer ...

Fibroblasts play a central role in maintaining healthy tissue structures, as well as in the development and progression of diseases. For a long time, these specialized connective tissue cells were ...

Researchers @hopkinskimmel and @HopkinsMed develop methods to predict which #livercancer patients do best with combination ...

Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.

EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTC: FCSC) today announced that its Phase 2 study to evaluate the safety and efficacy of azficel-T (LAVIV®) for the treatment of patients with ...